日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Retraction Note: PIWIL2 restrains the progression of thyroid cancer via interaction with miR-146a-3p

撤稿声明:PIWIL2 通过与 miR-146a-3p 相互作用抑制甲状腺癌的进展

Lu, Xiaoxiao; Zhu, Qingyun; Du, Hong; Gu, Mingjun; Li, Xiangqi

POGZ targeted by LINC01355/miR-27b-3p retards thyroid cancer progression via interplaying with MAD2L2.

POGZ 受 LINC01355/miR-27b-3p 的靶向作用,通过与 MAD2L2 相互作用来延缓甲状腺癌的进展

Lu Jiancan, Zhou Xinglu, Zhu Hongling, Zou Mei, Liu Lianyong, Li Xiangqi, Gu Mingjun

Correction: PIWIL2 restrains the progression of thyroid cancer via interaction with miR-146a-3p

更正:PIWIL2 通过与 miR-146a-3p 相互作用抑制甲状腺癌的进展

Lu, Xiaoxiao; Zhu, Qingyun; Du, Hong; Gu, Mingjun; Li, Xiangqi

Severe hydronephrosis complicated with primary aldosteronism: a case report and review of the literature

重度肾积水合并原发性醛固酮增多症:病例报告及文献综述

Sun, Jianjuan; Zeng, Qiurong; Lai, Longbing; Gu, Mingjun; Liu, Dingrong; Wu, Guangxiu; Peng, Chuan; Yang, Shuming; Li, Qifu; Lu, Jiangang

Perfusable Vessel-on-a-Chip for Antiangiogenic Drug Screening with Coaxial Bioprinting

利用同轴生物打印技术进行抗血管生成药物筛选的可灌注芯片容器

Zeming Gu, Mingjun Xie, Shang Lv, Nian Liu, Jing He, Yuanrong Li, Yuanbo Zhu, Jianzhong Fu, Hui Lin, Chaoqi Xie, Yong He

Asymptomatic Transmissibility Calls for Implementing a Zero-COVID Strategy to End the Current Global Crisis

无症状传播呼吁实施“清零新冠”战略以结束当前的全球危机

Zhang, Chaobao; Wang, Hongzhi; Wen, Zilu; Gu, Mingjun; Liu, Lianyong; Li, Xiangqi

New values of a type 2 taste receptor TAS2R14 in thyroid cancer

甲状腺癌中2型味觉受体TAS2R14的新价值

Liu, Lianyong; Zhu, Qingyun; Du, Hong; Shi, Chao; Gu, Mingjun; Li, Xiangqi

Assessment for the Correlation Between Diabetic Retinopathy and Metabolic Syndrome: A Cross-Sectional Study

糖尿病视网膜病变与代谢综合征相关性评估:一项横断面研究

Sun, Qing; Tang, Liang; Zeng, Qiurong; Gu, Mingjun

Osteoclasts May Affect Glucose Uptake-Related Insulin Resistance by Secreting Resistin

破骨细胞可能通过分泌抵抗素影响葡萄糖摄取相关的胰岛素抵抗。

Li, Xiangqi; Sun, Fei; Lu, Jiancan; Zhang, Jichen; Wang, Jingnan; Zhu, Hongling; Gu, Mingjun; Ma, Junhua

Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases

现有的用于对抗2019-nCoV相关传染病的苦味药物

Li, Xiangqi; Zhang, Chaobao; Liu, Lianyong; Gu, Mingjun